Bis(phenazine-1-carboxamides): Structure-activity relationships for a new class of dual topoisomerase I/II directed anticancer drugs

Journal of Medicinal Chemistry

Volumn 43, Issue 7, 2000, Pages 1350-1358

  Spicer, Julie A ^a   Gamage, Swarna A ^a   Rewcastle, Gordon W ^a   Finlay, Graeme J ^a   Bridewell, David J A ^a   Baguley, Bruce C ^a   Denny, William A ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DNA TOPOISOMERASE INHIBITOR; GYRASE INHIBITOR; PHENAZINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY TEST; DRUG EFFECT; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; STRUCTURE ACTIVITY RELATION;

AMIDES; ANIMALS; ANTINEOPLASTIC AGENTS; DNA TOPOISOMERASES, TYPE I; DNA TOPOISOMERASES, TYPE II; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; HUMANS; MICE; NEOPLASM TRANSPLANTATION; PHENAZINES; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 0342749301     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm990423f     Document Type: Article

References (26)

1. Bailly, C.; Brana, M.; Waring, M. J. Sequence-selective intercalation of antitumour bis-naphthalimides into DNA. Evidence for an approach via the major groove. Eur. J. Biochem. 1996, 240, 195-208
2. Bousquet, P. F.; Brana, M. F.; Conlon, D.; Fitzgerald, K. M.; Perron, D.; Cocchiaro, C.; Miller, R.; Moran, M.; George, J.; Qian, X.-D.; Keilhauer, G.; Romerdahl, C. A. Preclinical evaluation of LU 79553: a novel bis-naphthalimide with potent antitumor activity. Cancer Res. 1995, 55, 1176-1180.
3. Brana, M. F.; Castellano, J. M.; Moran, M.; Perez de Vega, M. J.; Perron, D.; Conlon, D.; Bousquet, P. F.; Romerdahl, C. A.; Robinson, S. P. Bis-naphthalimides 3: Synthesis and antitumor activity of N,N′-bis[2-(1,8-naphthalimido)ethyl]alkanediamines. Anti-Cancer Drug Design 1996, 11, 297-309.
4. Brana, M. F.; Castellano, J. M.; Perron, D.; Maher, C.; Conlon, D.; Bousquet, P. F.; George, J.; Qian, X.-D.; Robinson, S. P. Chromophore-modified bis-naphthalimides: synthesis and antitumor activity of bis-dibenz[de,h]isoquinoline-1,3-diones. J. Med. Chem. 1997, 40, 449-454.
5. Cherney, R. J.; Swartz, S. G.; Patten, A. D.; Akamike, E.; Sun, J.-H.; Kaltenbach, R. F.; Seitz, S. P.; Behrens, C. H.; Getahun, Z.; Trainor, G. L.; Vavala, M.; Kirshenbaum, M. R.; Papp, L. M.; Stafford, M. P.; Czerniak, P. M.; Diamond, R. J.; McRipley, R. J.; Page, R. J.; Gross, J. L. The synthesis and antitumor evaluation of unsymmetrical bis-imides. Bioorg. Med. Chem. Lett. 1997, 7, 163-168.
6. McRipley, R. J.; Burns-Horwitz, P. E.; Czerniak, P. M.; Diamond, R. J.; Diamond, M. A.; Miller, J. L. D.; Page, R. J.; Dexter, D. L.; Chen, S.-F.; Sun, J.-H.; Behrens, C. H.; Seitz, S. P.; Gross, J. L. Efficacy of DMP 840: a novel bis-naphthalimide cytotoxic agent with human solid tumor xenograft selectivity. Cancer Res. 1994, 54, 159-164.
7. Houghton, P. J.; Cheshire, P. J.; Hallman, J. C.; Gross, J. L.; McRipley, R. J.; Sun, J.-H.; Behrens, C. H.; Dexter, D. L.; Houghton, J. A. Evaluation of a novel bis-naphthalimide anticancer agent, DMP-840, against human xenografts derived from adult, juvenile, and pediatric cancers. Cancer Chemother. Pharmacol. 1994, 33, 265-272.
8. Thompson, J.; Pratt, C. B.; Stewart, C. F.; Avery, L.; Bowman, L.; Zamboni, W. C.; Pappo, A. Phase I study of DMP 840 in pediatric patients with refractory solid tumors. Inv. New Drugs 1998, 16, 45-49. O'Reilly, S.; Baker, S. D.; Sartorius, S.; Rowinsky, E. K.; Finizio, M.; Lubiniecki, G. M.; Grochow, L. B.; Gray, J. E.; Pieniaszek, H. J.; Donehower, R. C. A phase I and pharmacologic study of DMP 840 administered by 24-hour infusion. Ann. Oncol. 1998, 9, 101-1044.
9. Thompson, J.; Pratt, C. B.; Stewart, C. F.; Avery, L.; Bowman, L.; Zamboni, W. C.; Pappo, A. Phase I study of DMP 840 in pediatric patients with refractory solid tumors. Inv. New Drugs 1998, 16, 45-49. O'Reilly, S.; Baker, S. D.; Sartorius, S.; Rowinsky, E. K.; Finizio, M.; Lubiniecki, G. M.; Grochow, L. B.; Gray, J. E.; Pieniaszek, H. J.; Donehower, R. C. A phase I and pharmacologic study of DMP 840 administered by 24-hour infusion. Ann. Oncol. 1998, 9, 101-1044.
10. Kirshenbaum, M. R.; Chen, S.-F.; Behrens, C. H.; Papp, L. M.; Stafford, M. M.; Sun, J.-H.; Behrens, D. L.; Fredericks, J. R.; Polkus, S. T.; Sipple, P.; Patten, A. D.; Dexter, D.; Seitz, S. P.; Gross, J. L. (R,R)-2,2′-[1,2-ethanediylbis[imino(1-methyl-2,1-ethanediyl)]]-bis[5- nitro-1H-benz[de]isoquinoline-1,3-(2H)-dione] dimethanesulfonate (DMP 840), a novel bis-naphthalimide with potent nonselective tumoricidal activity in vitro. Cancer Res. 1994, 54, 2199-2206.
11. Spicer, J. A.; Gamage, S. A.; Atwell, G. J.; Finlay, G. J.; Baguley, B. C.; Denny, W. A. Dimeric analogues of noncationic tricyclic carboxamides are a new class of cytotoxic agents. Anti-Cancer Drug Des. 1999, 14, 281-289.
12. Gamage, S. A.; Spicer, J. A.; Atwell, G. J.; Finlay, G. J.; Baguley, B. C.; Denny, W. A. Structure-activity relationships for substituted bis(acridine-4-carboxamides): a new class of anticancer agents. J. Med. Chem. 1999, 42, 2383-2393.
13. Robertson, I. G. C.; Palmer, B. D.; Officer, M.; Siegers, D. J.; Paxton, J. W.; Shaw, G. J. Cytosol mediated metabolism of the experimental antitumour agent acridine carboxamide to the 9-acridone derivative. Biochem. Pharmacol. 1991, 42, 1879-1884.
14. Rewcastle, G. W.; Denny, W. A.; Baguley, B. C. Potential Antitumor Agents. 51. Synthesis and antitumor activity of substituted phenazine-1-carboxamides. J. Med. Chem. 1987, 30, 843-851.
15. Rewcastle, G. W.; Denny, W. A. Unequivocal synthesis of phenazine-1-carboxylic acids: selective displacement of fluorine during alkaline borohydride reduction of N-(2-fluorophenyl)-3-nitroanthranilic acids. Synth. Commun. 1987, 17, 1171-1179.
16. Goldstein, H.; Schaaf, E. Nitration of 2-nitro-4-chlorobenzoic acid. Helv. Chim. Acta 1957, 11, 369-372.
17. Atwell, G. J.; Rewcastle, G. W.; Baguley, B. C.; Denny, W. A. Potential antitumor agents. 50. In vivo solid tumor activity of derivatives of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide. J. Med. Chem. 1987, 30, 664-669.
18. Wilkoff, L. J.; Dulmadge, E.; Chopra, D. P. Viability of cultured Lewis lung cell populations exposed to β-retinoic acid (40753). Proc. Soc. Exp. Biol. Med. 1980, 163, 233-236.
19. Finlay, G. J.; Baguley, B. C.; Snow, K.; Judd, W. Multiple patterns of resistance of human leukemia cell sublines to amsacrine analogues. J. Natl. Cancer Inst. 1990, 82, 662-667.
20. Finlay, G. J.; Holdaway, K. M.; Baguley, B. C. Comparison of the effects of genistein and amsacrine on leukemia cell proliferation. Oncol. Res. 1994, 6, 33-37.
21. Finlay, G. J.; Riou, J.-F.; Baguley, B. C. From amsacrine to DACA (N-[2-(dimethylamino)ethyl]acridine-4-carboxamide): selectivity for topoisomerases I and II among acridine derivatives. Eur. J. Cancer 1996, 32A, 708-714.
22. Monks, A.; Scudiero, D.; Skehan, P.; Shoemaker, R.; Paull, K.; Vistica, D.; Hose, C.; Langley J.; Cronise, P.; Vaigro-Wolff, A.; Gray-Goodrich, M.; Campbell, H.; Mayo, J.; Boyd, M. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J. Natl. Cancer Inst. 1991, 83, 757-766.
23. Baguley, B. C.; Zhuang, L.; Marshall, E. M. Experimental solid tumour activity of N-[2-(dimethylamino)ethyl]-acridine-4-carboxamide. Cancer Chemother. Pharmacol. 1995, 36, 244-248.
24. Marshall, E. S.; Finlay, G. J.; Matthews, J. H. L.; Shaw, J. H. F.; Nixon, J.; Baguley, B. C. Microculture-based chemosensitivity testing: a feasibility study comparing freshly explanted melanoma cells with human melanoma cell lines. J. Natl. Cancer Inst. 1992, 84, 340-345.
25. Skehan, P.; Storeng. R.; Scudiero, D.; Monks, A.; McMahon. J.; Vistica, D.; Warren, J. T.; Bokesch, H.; Kenney, S.; Boyd, M. R. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst. 1990, 82, 1107-1112.
26. Bridewell, D. J. A.; Finlay, G. J.; Baguley, B. C. Mechanism of cytotoxicity of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide and of its 7-chloro derivative: the roles of topoisomerase I and II. Cancer Chemother. Pharmacol. 1999, 43, 302-308.